Search

Copyright of Journal of Nanjing Medical University: Natural Sciences is the property of Journal of Nanjing Medicial University (NMU) Medical Publications Center and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective This paper reports a case of malignant intracranial hypertension, reviews his diagnosis and treatment, and analyzes his etiology, in order to improve the clinicians' cognition of this disease. Methods and Results The patient was a 19-year-old male with subacute onset and chronic course of disease, presenting with amaurosis, headache, neck and shoulder pain, blurred vision and tinnitus disease. Imaging findings showed cerebral venous sinus stenosis (VSS) with obvious pressure difference at both ends of stenosis. However, venous sinus stenting was ineffective. After optic nerve sheath decompression, the symptoms of headache and blurred vision were not significantly improved. Finally, the patient was diagnosed as glioblastoma (WHO IV), and died 8 months after removal of the tumor foci. Conclusions Patients with the pressure difference at both ends of malignant intracranial hypertension with VSS should not take stenting. Clarifying the cause and type of stenosis is very important for correct diagnosis and guide treatment. [ABSTRACT FROM AUTHOR]

Copyright of Cancer Research on Prevention & Treatment is the property of Cancer Research on Prevention & Treatment Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Diagnostic Imaging & Interventional Radiology is the property of Editorial Office of Diagnostic Imaging & Interventional Radiology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Glioma is the most common primary intracranial tumor, and most patients present as glioblastoma, with high morbidity and mortality. The prognosis of patients with glioblastoma remains poor after surgical resection combined with standardized treatment of radiotherapy and chemotherapy. In recent years, although the breakthrough of immunotherapy have been achieved in the treatment of a variety of solid tumors, the existing data show that immunotherapy is not effective in improving the survival of patients with glioblastoma. However, studies have shown that immunotherapy can have a synergistic effect with radiotherapy which can increase antigen presentation and promote the formation of pro-inflammatory tumor microenvironment, providing more relevant targets for immunotherapy. The purpose of this paper is to discuss the effect of radiotherapy on tumor immune microenvironment and the role of radiotherapy combined with immune checkpoint inhibitors in the treatment of glioblastoma.